Researchers reported that ZNF274 helps drive a lineage-switch program in pancreatic cancer and, in turn, fuels resistance to CDK7-targeted therapy. The work frames ZNF274 as a regulatory node connecting phenotypic plasticity to how tumor cells respond under CDK7 inhibition. The study’s central thrust is molecular: a zinc-finger protein controlling splicing/regulatory behavior (via transcription start-site complexity described elsewhere) is echoed here as a driver of cancer cell identity shifts that can blunt drug efficacy. The resistance linkage is positioned as a potential stratification or combination opportunity. For drug developers, the actionable takeaway is that CDK7 resistance may not be purely pathway-level and could be mediated through lineage-state transitions. That expands the target landscape for overcoming resistance beyond simply escalating or switching CDK7 inhibitors. Next steps for the field will be validating ZNF274 as a predictive biomarker and testing whether blocking the lineage-switch circuitry can resensitize tumors to CDK7 inhibitors.